Sidra Medicine has showcased its latest surgical and clinical research milestones at the Paediatric & Congenital Interventional Cardiac Symposium (PICS) held from September 7-10 in Chicago, US.
PICS is an annual symposium featuring live operations and the latest research breakthroughs in interventional cardiology for congenital and structural heart disease.
Prof Ziyad M Hijazi, chief medical officer at Sidra Medicine as well as the president of the PICS Society and director of the PICS symposium said: “I am very proud of the milestones the Heart Centre at Sidra Medicine has achieved. Our life saving and pioneering treatment programmes have not only changed the lives of our patients in Qatar but from across the Middle East, Asia and Africa. We were happy to share updates about our programmes for patients with Congenital Heart Disease, with over 700 interventional cardiologists from more than 60 countries at PICS.”
“The strength of some of our healthcare and research programmes, has positioned Sidra Medicine as a ground-breaking healthcare provider that is leading the way in patient care. In fact, one of our successful valve implantation programmes that was performed in Qatar is now being considered by the Food and Drug Administration in the United States for a trial in the US, following its successful CE certification in April 2022,” added Prof Hijazi.
Prof Hijazi has been the global principal investigator for a consortium of international cardiac interventionists to evaluate the Venus P-valve. The valve, addresses the needs of a large majority of CHD patients who are unable to benefit from existing minimally-invasive valve implants.
Prof Ziyad M Hijazi, chief medical officer at Sidra Medicine as well as the president of the PICS Society and director of the PICS symposium said: “I am very proud of the milestones the Heart Centre at Sidra Medicine has achieved. Our life saving and pioneering treatment programmes have not only changed the lives of our patients in Qatar but from across the Middle East, Asia and Africa. We were happy to share updates about our programmes for patients with Congenital Heart Disease, with over 700 interventional cardiologists from more than 60 countries at PICS.”
“The strength of some of our healthcare and research programmes, has positioned Sidra Medicine as a ground-breaking healthcare provider that is leading the way in patient care. In fact, one of our successful valve implantation programmes that was performed in Qatar is now being considered by the Food and Drug Administration in the United States for a trial in the US, following its successful CE certification in April 2022,” added Prof Hijazi.
Prof Hijazi has been the global principal investigator for a consortium of international cardiac interventionists to evaluate the Venus P-valve. The valve, addresses the needs of a large majority of CHD patients who are unable to benefit from existing minimally-invasive valve implants.
